These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 25385341

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Human hepatocytes derived from pluripotent stem cells: a promising cell model for drug hepatotoxicity screening.
    Gómez-Lechón MJ, Tolosa L.
    Arch Toxicol; 2016 Sep; 90(9):2049-2061. PubMed ID: 27325232
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Toxicity testing and drug screening using iPSC-derived hepatocytes, cardiomyocytes, and neural cells.
    Csöbönyeiová M, Polák Š, Danišovič L.
    Can J Physiol Pharmacol; 2016 Jul; 94(7):687-94. PubMed ID: 27128322
    [Abstract] [Full Text] [Related]

  • 9. Transcriptional, Functional, and Mechanistic Comparisons of Stem Cell-Derived Hepatocytes, HepaRG Cells, and Three-Dimensional Human Hepatocyte Spheroids as Predictive In Vitro Systems for Drug-Induced Liver Injury.
    Bell CC, Lauschke VM, Vorrink SU, Palmgren H, Duffin R, Andersson TB, Ingelman-Sundberg M.
    Drug Metab Dispos; 2017 Apr; 45(4):419-429. PubMed ID: 28137721
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A comparison of hepato-cellular in vitro platforms to study CYP3A4 induction.
    Bulutoglu B, Rey-Bedón C, Mert S, Tian L, Jang YY, Yarmush ML, Usta OB.
    PLoS One; 2020 Apr; 15(2):e0229106. PubMed ID: 32106230
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pluripotent stem cell derived hepatocyte like cells and their potential in toxicity screening.
    Greenhough S, Medine CN, Hay DC.
    Toxicology; 2010 Dec 30; 278(3):250-5. PubMed ID: 20674645
    [Abstract] [Full Text] [Related]

  • 14. Critical differences in drug metabolic properties of human hepatic cellular models, including primary human hepatocytes, stem cell derived hepatocytes, and hepatoma cell lines.
    Kvist AJ, Kanebratt KP, Walentinsson A, Palmgren H, O'Hara M, Björkbom A, Andersson LC, Ahlqvist M, Andersson TB.
    Biochem Pharmacol; 2018 Sep 30; 155():124-140. PubMed ID: 29953844
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Concentration-dependent toxicogenomic changes of silver nanoparticles in hepatocyte-like cells derived from human induced pluripotent stem cells.
    Gao X, Li R, Sprando RL, Yourick JJ.
    Cell Biol Toxicol; 2021 Apr 30; 37(2):245-259. PubMed ID: 32447489
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Toxicological applications of human induced pluripotent stem cell-derived hepatocyte-like cells: an updated review.
    Gao X, Yourick JJ, Sprando RL.
    J Toxicol Sci; 2023 Apr 30; 48(8):441-456. PubMed ID: 37532578
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.